CN1325098C - 一种提高免疫力的中药组合物及制备方法和质量控制方法 - Google Patents
一种提高免疫力的中药组合物及制备方法和质量控制方法 Download PDFInfo
- Publication number
- CN1325098C CN1325098C CNB2004100988050A CN200410098805A CN1325098C CN 1325098 C CN1325098 C CN 1325098C CN B2004100988050 A CNB2004100988050 A CN B2004100988050A CN 200410098805 A CN200410098805 A CN 200410098805A CN 1325098 C CN1325098 C CN 1325098C
- Authority
- CN
- China
- Prior art keywords
- solution
- chinese medicine
- radix
- medicine composition
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000003908 quality control method Methods 0.000 title claims abstract description 13
- 230000036039 immunity Effects 0.000 title claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 25
- 239000009636 Huang Qi Substances 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 128
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 238000012360 testing method Methods 0.000 claims description 68
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 36
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000013558 reference substance Substances 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 27
- 238000004809 thin layer chromatography Methods 0.000 claims description 27
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000741 silica gel Substances 0.000 claims description 17
- 229910002027 silica gel Inorganic materials 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 15
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 14
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 238000010828 elution Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 8
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 206010011224 Cough Diseases 0.000 claims description 6
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 6
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 239000002390 adhesive tape Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000003480 eluent Substances 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 230000000274 adsorptive effect Effects 0.000 claims description 5
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 claims description 5
- 238000012850 discrimination method Methods 0.000 claims description 5
- 230000003760 hair shine Effects 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 4
- AZLPEJUVWWGLHA-UHFFFAOYSA-N ethyl acetate;hexane;methanol Chemical compound OC.CCCCCC.CCOC(C)=O AZLPEJUVWWGLHA-UHFFFAOYSA-N 0.000 claims description 4
- 208000026435 phlegm Diseases 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000000890 drug combination Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002180 anti-stress Effects 0.000 claims description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 4
- 210000004072 lung Anatomy 0.000 abstract description 15
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 3
- 208000033065 inborn errors of immunity Diseases 0.000 abstract 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 77
- 239000003795 chemical substances by application Substances 0.000 description 46
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 45
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 45
- 235000021286 stilbenes Nutrition 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 40
- 230000037396 body weight Effects 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 24
- 230000003203 everyday effect Effects 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 206010006458 Bronchitis chronic Diseases 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 206010006451 bronchitis Diseases 0.000 description 16
- 208000007451 chronic bronchitis Diseases 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 210000000981 epithelium Anatomy 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 206010018691 Granuloma Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 8
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 7
- 241000545442 Radix Species 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000003437 trachea Anatomy 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 206010002660 Anoxia Diseases 0.000 description 5
- 241000976983 Anoxia Species 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 244000061176 Nicotiana tabacum Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 230000007953 anoxia Effects 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000037976 chronic inflammation Diseases 0.000 description 5
- 230000006020 chronic inflammation Effects 0.000 description 5
- 210000004081 cilia Anatomy 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002175 goblet cell Anatomy 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002026 chloroform extract Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 208000029039 cyanide poisoning Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000015612 Complement 3b Receptors Human genes 0.000 description 2
- 108010024114 Complement 3b Receptors Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000000254 ciliated cell Anatomy 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101710126949 Lysin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
水平因素 | 煎煮时间(h) | 煎煮次数 | 煎煮用水量(倍数) |
123 | 0.751.01.5 | 123 | 578 |
方差来源 | 离均平方和 | 自由度 | 方差 | F值 | 显著性 |
ABCD | 16.6319.730.06670.0733 | 2222 | 8.3159.8650.03340.0367 | 226.57268.800.910 | 高度显著高度显著不显著 |
S总=36.50 |
组号 | 1 | 2 | 3 | SA2=1.7344SA3=1.8346S2 A2=3.0082S2 A3=3.3658F=S2 A2/S2 A3=0.8973F1-0.05(2,2)=19.0F<F1-0.05(2,2) |
A2A3 | 9.529.65 | 12.6512.75 | 12.3812.90 |
组号 | 1 | 2 | 3 | SB2=1.7344SB3=1.8346S2 B2=3.0082S2 B3=3.3658F=S2 B2/S2 B3=0.8973F1-0.05(2,2)=19.0F<F1-0.05(2,2) |
B2B3 | 9.6510.05 | 12.6512.38 | 12.7512.90 |
温度(℃) | 40 | 60 | 80 |
黄芪甲苷含量(mg/g) | 0.068 | 0.082 | 0.081 |
批号 | 970102 | 970301 | 970501 |
含量 | 0.404 | 0.408 | 0.407 |
组别 | 动物数 | 剂量(g/kg) | 肉芽肿重量(mg/100g体重) |
空白对照组低剂组高剂组药物对照组 | 8888 | -1.102.203.75 | 64.32±5.4555.43±6.61*△47.00±8.80**56.75±6.90*△ |
组别 | 动物数 | 剂量(g/kg) | 肉芽肿重量(mg/100g体重) |
空白对照组低剂组高剂组药物对照组 | 8888 | -1.102.203.75 | 332.59±22.15309.68 ±32.73*292.10±28.00**302.34±31.84* |
组别 | 动物数 | 剂量(g/kg) | 肿胀率 | ||||
30min | 1h | 2h | 3h | 4h | |||
空白对照组低剂组高剂组药物对照组 | 8888 | -1.102.203.75 | 60.91±23.0363.92±12.1169.22±14.1871.53±23.03 | 62.58±23.7659.79±14.88(4.46)56.99±21.72(8.93)71.96±23.65 | 55.66±21.2252.41±12.07(5.84)37.05±16.55(33.44)51.18±22.63 | 35.35±23.4331.93±16.01(9.07)24.38±16.93(31.03)30.35±11.12 | 28.28±16.8121.95±12.30(22.36)21.35±16.92(24.48)24.10±15.53 |
分组 | n | 剂量(g/kg) | 总抗氧化力(单位/ml) |
空白对照组造模组低剂量组高剂量组药物对照组 | 1010101010 | --2.5g/kg5.0g/kg7.5g/kg | 14.31±2.078.91±1.05△△10.32±1.23*13.08±1.96**12.67±1.73** |
分组 | n | 剂量(g/kg) | T-SOD(NU/mg蛋白) |
空白对照组造模对照组低剂量组高剂量组药物对照组 | 1010101010 | --2.5g/kg5.0g/kg7.5g/kg | 0.90±0.150.67±0.16△0.84±0.14*1.40±0.15**1.26±0.12** |
组别(n=10) | 剂量(g/kg) | 丙二醛含量(nM/ml) |
正常对照组造模组低剂组高剂组参苏丸组 | --2.55.07.5 | 9.35±1.5414.97±2.13△△12.86±1.78*10.77±0.99**11.23±1.46** |
组别 | n | 剂量(g/kg) | Na+,k+-ATP酶活力(μmolpi/mgprot/h) |
空白对照组造模对照组低剂量组高剂量组药物对照组 | 1010101010 | --2.55.07.5 | 40.09±5.8642.95 ±4.29△38.51±3.4436.18±5.80*36.56±4.56* |
组别 | N | 剂量(g/kg) | 存活时间(min) |
正常对照组低剂组高剂组药物对照组 | 10101010 | -2.55.07.5 | 88.50±25.13103.80±53.18113.10±26.16*108.00±41.39 |
组别 | n | 剂量(g/kg) | 生存时间(min) |
正常对照组低剂组高剂组药物对照组 | 991010 | -2.55.07.5 | 4.68±0.595.86±1.978.69±4.05*6.75±2.53 |
组别 | n | 剂量(g/kg) | 存活时间(min) |
正常对照组低剂组高剂组药物对照组 | 10101010 | -2.55.07.5 | 25.00±9.2128.80±10.4038.20±11.23*28.20±9.30 |
组别 | n | 剂量(g/kg) | 血清溶血素OD值 |
正常免疫组环磷酰胺组芪风固表低剂组芪风固表中剂组芪风固表高剂组阳性药物对照组 | 101010101010 | --2.55.010.015.0 | 1.42±0.140.82±0.14△△0.92±0.161.26±0.11*1.36±0.18**1.29±0.14** |
组别 | 动物数(只) | 剂量(g/kg) | C3b受体花环率(%) | C3b免疫复合物花环率(%) |
空白对照组模型组低剂组高剂组参苏丸组 | 1010101010 | --2.55.07.5 | 14.9±5.88.3±3.1△△9.7±4.513.3±4.2**13.4±5.7** | 8.9±3.216.7±5.4△△13.2±6.610.4±3.4**10.5±2.5** |
组别 | n | 剂量(g/kg) | 血中残留刚果红(μg/ml) |
正常对照组低剂组高剂组阳性药对照组 | 99109 | -2.55.07.5 | 5.03±1.414.22±1.123.40±0.68**4.21±0.98 |
组别 | n | 剂量(g/kg) | 溶菌酶含量(μg/ml) |
空白对照组模型组(环磷酰胺)低剂组高剂组阳性药对照组 | 1010101010 | --2.55.07.5 | 6.68±3.504.12±1.64△5.12±2.346.61±3.12*6.55±2.11* |
组别 | 动物数 | 剂量(g/kg) | 胸腺指数 | 脾指数 |
空白对照组模型组低剂组高剂组阳性药对照组 | 1010101010 | --2.55.07.5 | 2.71±0.731.68±0.71△2.00±0.992.77±0.79**2.06±0.54 | 3.72±1.012.98±0.673.02±0.583.83±0.86*3.58±0.63 |
组别 | 动物数 | 剂量(g/kg) | 干扰素效价(log4/ml) |
空白对照组低剂量组高剂量组 | 61111 | 5.0g/kg7.5g/kg | 没检出1.72±0.792.59±0.65 |
标准品 | 6.1 |
组别n=8 | 剂量(g/kg) | 气管酚红排泌量(μg/ml) |
空白对照组低剂量组高剂量组阳性药对照组 | 等体积生理盐水5g/kg7.5g/kg12.5gkg | 0.227±0.0500.362±0.1590.543±0.124**0.320±0.147 |
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100988050A CN1325098C (zh) | 2004-12-17 | 2004-12-17 | 一种提高免疫力的中药组合物及制备方法和质量控制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100988050A CN1325098C (zh) | 2004-12-17 | 2004-12-17 | 一种提高免疫力的中药组合物及制备方法和质量控制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1788775A CN1788775A (zh) | 2006-06-21 |
CN1325098C true CN1325098C (zh) | 2007-07-11 |
Family
ID=36787018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100988050A Active CN1325098C (zh) | 2004-12-17 | 2004-12-17 | 一种提高免疫力的中药组合物及制备方法和质量控制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1325098C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670793B (zh) * | 2012-05-04 | 2014-04-30 | 山西华诚睿光生物科技股份有限公司 | 提高奶牛免疫力、降低牛奶体细胞数的中药制剂及制备方法 |
CN104027470A (zh) * | 2013-03-10 | 2014-09-10 | 高见 | 一种增强机体抵抗能力防治感冒的中药 |
CN103798473A (zh) * | 2014-01-16 | 2014-05-21 | 戴明传 | 延年益寿养生保健茶 |
CN104982777A (zh) * | 2015-06-17 | 2015-10-21 | 蚌埠市天星树脂有限责任公司 | 一种健脾益气保健药品原药提取所用树脂及其制备方法 |
CN109077325A (zh) * | 2018-04-24 | 2018-12-25 | 恩施德源健康科技发展有限公司 | 一种高效增强免疫力的富硒植物肽制品及其制备方法和应用 |
CN109010506A (zh) * | 2018-09-18 | 2018-12-18 | 右江民族医学院 | 一种增强免疫力的口服液及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113778A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 老年病制剂 |
CN1310003A (zh) * | 2001-02-19 | 2001-08-29 | 孟庆云 | 中西医治疗肺气肿的药物 |
-
2004
- 2004-12-17 CN CNB2004100988050A patent/CN1325098C/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113778A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 老年病制剂 |
CN1310003A (zh) * | 2001-02-19 | 2001-08-29 | 孟庆云 | 中西医治疗肺气肿的药物 |
Non-Patent Citations (1)
Title |
---|
补中益气汤在提高机体免疫力方面的应用100例临床观察 何晓凤 等,现代中医药,第2期 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN1788775A (zh) | 2006-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101396544B (zh) | 宣肺平喘的中药组合物及其制备方法 | |
CN103222988B (zh) | 一种美洲大蠊提取物及其制备方法和应用 | |
CN102590433B (zh) | 一种肝畅制剂的质量检测方法 | |
CN101455690A (zh) | 治疗小儿食积的中药组合物及其制备方法和质量控制方法 | |
CN101310751A (zh) | 一种具有益气养血作用的中药组合物及其制备方法和质量控制方法 | |
CN104225524A (zh) | 栝楼桂枝汤在制备治疗或/和预防认知功能障碍的药物中的用途 | |
CN1325098C (zh) | 一种提高免疫力的中药组合物及制备方法和质量控制方法 | |
CN102305839A (zh) | 宣肺平喘的中药组合物的检测方法 | |
CN1985864B (zh) | 一种主要由甘草酸或其盐、人参和灵芝制成的药物组合物 | |
CN101843884B (zh) | 用于治疗手足口病的抗病毒口服液的质量检测方法 | |
CN105434894A (zh) | 一种制备治疗系统性红斑狼疮的中药组合物的方法 | |
CN102288701B (zh) | 宣肺平喘的中药组合物的检测方法 | |
CN107041924A (zh) | 一种防治糖尿病肾病的朝药复方提取物及其制备方法 | |
CN101632746B (zh) | 一种治疗溃疡性结肠炎的药物及其制备方法 | |
CN110292617A (zh) | 肺力咳胶囊浸膏及其用途和质量控制方法 | |
CN101804083B (zh) | 松花粉及其提取物在治疗炎症性肠病中的用途及该提取物的制备方法 | |
CN101461903A (zh) | 一种治疗咽喉肿痛大便秘结的中药组合物及其制备方法 | |
CN101461904A (zh) | 一种治疗咽喉肿痛大便秘结的中药组合物的检验方法 | |
CN105521256B (zh) | 一种林蛙油平贝母软胶囊及其制备方法和用途 | |
CN107320659A (zh) | 一种用于治疗溃疡性结肠炎的中药组合物及其制备方法 | |
CN104288238B (zh) | 一种治疗肠易激综合症的药物及其制备方法与检测方法 | |
CN102988552A (zh) | 一种治疗鸡大肠杆菌病的中药复方白头翁颗粒及其制备方法和应用 | |
CN101181563A (zh) | 橘红痰咳制剂及制备方法和质量控制方法 | |
CN106928376A (zh) | 山茱萸多糖的分离方法及其应用 | |
CN101829258B (zh) | 一种健脾养胃,补血生津中药组合物制剂的质量检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201231 Address after: 150036 No. 142, three auxiliary street, Xiangfang District, Heilongjiang, Harbin Patentee after: HEILONGJIANG ACADEMY OF TCM Address before: 150036 No. 142, three auxiliary street, Xiangfang District, Heilongjiang, Harbin Patentee before: Wang Weiming |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210118 Address after: 410000 no.194, Section 1, Furong Middle Road, Kaifu District, Changsha City, Hunan Province Patentee after: Hunan Anbang Pharmaceutical Co., Ltd Address before: 150036 No. 142, three auxiliary street, Xiangfang District, Heilongjiang, Harbin Patentee before: HEILONGJIANG ACADEMY OF TCM |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 410300 no.283, Kangning Road, Liuyang economic and Technological Development Zone, Changsha City, Hunan Province Patentee after: Hunan Anbang Pharmaceutical Co., Ltd Address before: 410000 no.194, Section 1, Furong Middle Road, Kaifu District, Changsha City, Hunan Province Patentee before: Hunan Anbang Pharmaceutical Co., Ltd |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220512 Address after: 150221 North District of Niujia Industrial Park, Niujia Town, Wuchang City, Harbin, Heilongjiang Province Patentee after: Anbang Pharmaceutical (Harbin) Co.,Ltd. Address before: 410300 no.283, Kangning Road, Liuyang economic and Technological Development Zone, Changsha City, Hunan Province Patentee before: Hunan Anbang Pharmaceutical Co.,Ltd. |